[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341076-105":59,"doc-detail-341076-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","advancements-in-psma-ligand-radiolabeling-for-diagnosis-and-treatment-of-prostate-cancer-a-systematic-review","Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer - a systematic review","","Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer - a systematic review. Prostate cancer progresses from the prostate to organs including lymph nodes and bones, and often becomes resistant to castration therapy, requiring new strategies. The review explains radioligand therapy (RLT), which delivers radionuclides to lesions via targeted carriers to destroy cancer tissue. It highlights PET approaches targeting PSMA and key FDA-approved agents such as 68Ga-PSMA-11 and 177Lu-PSMA-617.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancements-in-psma-ligand-radiolabeling-for-diagnosis-and-treatment-of-prostate-cancer-a-systematic-review/341076/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancements-in-psma-ligand-radiolabeling-for-diagnosis-and-treatment-of-prostate-cancer-a-systematic-review/341076.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of radioligand therapy (RLT) in this review?","Question",{"text":113,"@type":114},"RLT delivers radionuclide drugs to prostate cancer lesions using specific carriers or technologies, and the released radioactive energy destroys cancer cell tissues.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which PSMA-targeting agents are highlighted as milestones?",{"text":118,"@type":114},"The review emphasizes FDA-approved PSMA-targeting agents including 68Ga-PSMA-11 and 177Lu-PSMA-617.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is early diagnosis and precise evaluation important for prostate cancer?",{"text":122,"@type":114},"Early detection supports timely intervention and can help manage progression toward castration-resistant prostate cancer, which is identified as a primary cause of death.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},341076,1790181807,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","TYPE Review  \nPUBLISHED 21 March 2024  \nDOI 10.3389/fonc.2024.1373606  \nOPEN ACCESS  \nEDITED BY  \nVikas Prasad,  \nRadiology Mallinckrodt Institute of Radiology Division of Nuclear Medicine Washington University, United States  \nREVIEWED BY Xiaotian Xia,  \nHuazhong University of Science and Technology, China  \nKip E. Guja,  \nStanford University, United States  \n*CORRESPONDENCE Yue Chen  \n [chenyue5523@126.com](chenyue5523@126.com)  \n†These authors have contributed equally to this work  \nRECEIVED 20 January 2024  \nACCEPTED 08 March 2024  \nPUBLISHED 21 March 2024  \nCITATION  \nYan Y, Zhuo H, Li T, Zhang J, Tan M and Chen Y (2024) Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review.  \nFront. Oncol. 14:1373606 .  \ndoi: 10.3389/fonc.2024.1373606  \nCOPYRIGHT  \n© 2024 Yan, Zhuo, Li, Zhang, Tan and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAdvancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer: a systematic review  \nYuanzhuo Yan 1,2,3†, Huixian Zhuo 4†, Tengfei Li 1,2,3, Jintao Zhang 1,2,3, Min Tan 1,2,3 and Yue Chen 1,2,3*  \n1 Department of Nuclear Medicine, The Afﬁliated Hospital of Southwest Medical University, Luzhou, Sichuan, China, 2 Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, China, 3 Nuclear Medicine Institute of Southwest Medical University, Luzhou, Sichuan, China, 4 Department of Medical Imaging, Southwest Medical University, Luzhou, Sichuan, China  \nProstate cancer(PCa), a leading global health concern, profoundly impacts millions of men worldwide. Progressing through two stages, it initially develops within the prostate and subsequently extends to vital organs such as lymph nodes, bones, lungs, and the liver. In the early phases, castration therapy is often employed to mitigate androgen effects. However, when prostate cancer becomes resistant to this treatment, alternative strategies become imperative. As diagnostic and treatment methodologies for prostate cancer continually advance, radioligand therapy (RLT) has emerged as a promising avenue, yielding noteworthy outcomes. The fundamental principle of RLT involves delivering radionuclide drugs to cancerous lesions through speciﬁc carriers or technologies. Subsequently, these radionuclide drugs release radioactive energy, facilitating the destruction of cancer cell tissues. At present, the positron emission tomography (PET) targeting PSMA has been widely developed for the use of diagnosis and staging of PCa. Notably, FDA-approved prostate-speciﬁc membrane antigen (PSMA) targeting agents, such as 68Ga-PSMA-11 and 177 LuPSMA-617, represent signiﬁcant milestones in enhancing diagnostic precision and therapeutic efﬁcacy. This review emphasizes the current research status and outcomes of various radionuclide-labeled PSMA ligands. The objective is to provide valuable insights for the continued advancement of diagnostic and therapeutic approaches in the realm of prostate cancer.  \nKEYWORDS  \nPSMA, prostate cancer, mCRPC, radiolabeled, RLT, Tat, PET/CT  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nAs of 2020, the global landscape of cancer incidence and mortality reveals a staggering burden, with around 19.3 million new cancer cases reported worldwide (excluding non-melanoma skin cancer) . Unfortunately, approximately 10 million cancer patients succumbed to the disease (excluding non-melanoma skin cancer) . Prostate cancer constituted a signiﬁcant portion of these cases, with approximately 1.4 million ne","cbCairEu0HVRkWzE","https://ap.wps.com/l/cbCairEu0HVRkWzE","pdf",2157065,"English","# Introduction\n# PSMA Ligand Radiolabeling in Diagnosis and Treatment\n## Radioligand Therapy Mechanism and Clinical Rationale\n## PET/CT Agents and Current Evidence\n# Conclusion and Future Directions","[{\"question\":\"What is the main purpose of radioligand therapy (RLT) in this review?\",\"answer\":\"RLT delivers radionuclide drugs to prostate cancer lesions using specific carriers or technologies, and the released radioactive energy destroys cancer cell tissues.\"},{\"question\":\"Which PSMA-targeting agents are highlighted as milestones?\",\"answer\":\"The review emphasizes FDA-approved PSMA-targeting agents including 68Ga-PSMA-11 and 177Lu-PSMA-617.\"},{\"question\":\"Why is early diagnosis and precise evaluation important for prostate cancer?\",\"answer\":\"Early detection supports timely intervention and can help manage progression toward castration-resistant prostate cancer, which is identified as a primary cause of death.\"}]","Advancements in PSMA ligand radiolabeling for diagnosis and treatment of prostate cancer - a systematic review | PDF",1790040171,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/883c8e481eceb0002744cc41d30c34c2.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/babaae9e6502b129d8b922737d187618.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d2bc8081dea67de75f438339a327859.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c33fe937955f9456d423f29c0a745de3.webp",980,1385]